{"nctId":"NCT00308685","briefTitle":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics","startDateStruct":{"date":"2006-06-10","type":"ACTUAL"},"conditions":["Asthma"],"count":95,"armGroups":[{"label":"Albuterol-HFA-BAI","type":"EXPERIMENTAL","interventionNames":["Drug: Albuterol"]},{"label":"Placebo-HFA-BAI","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Albuterol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening\n* Male and female children aged 4-11 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 60-90%\n* Ability to perform spirometry\n* Demonstrate 12% airways reversibility\n\nExclusion Criteria:\n\n* Require continuous treatment with beta-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids\n* Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22","description":"The baseline FEV1 was defined as the average of the two predose measurements ( at -0.5 and 0.0 hour) on the test day (Day 22). The mean was obtained from the analysis of covariance (ANCOVA) adjusted for baseline FEV1 and the pooled investigational center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.807","spread":"0.954"},{"groupId":"OG001","value":"8.644","spread":"1.044"}]}]}]},{"type":"SECONDARY","title":"Baseline-Adjusted Area Under the Percent-Predicted FEV1 Versus Time Curve Over 6 Hours (PPFEV1 AUEC0-6) at Day 22","description":"Baseline-adjusted PPFEV1 AUEC0-6 on Study Day 22 was determined using both the Day 1 and Day 22 baselines.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.473","spread":"4.033"},{"groupId":"OG001","value":"11.672","spread":"4.476"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.182","spread":"6.036"},{"groupId":"OG001","value":"6.767","spread":"6.572"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":[]}}}